 MaxCyte has become the go-to partner for biotech companies using non-viral cell engineering, aided by its proprietary patented flow electroporation technology. The company has a scalable licenses and SPLs business model with recurring revenues. Milestone and royalty payments at 100 gross margins are set to account for a larger percentage of revenues over time. 